The Company’s business model is very simple.  Genesis relies on its core competency – research and development – to generate value.  Genesis has a solid track record in discovering, patenting, and validating disease biomarkers.  Furthermore, the Company is an expert in the development and optimization of molecular diagnostic tests targeted at its biomarker discoveries.  This concentrated approach and relentless focus on its core competencies allows Genesis to create significant, non-linear revenue growth through the introduction of literally dozens of new diagnostics products over relatively short timeframes.

Moving forward, the Company will continue to exploit its competencies, target billion dollar global markets, work with globally-oriented strategic partners, and penetrate global markets with its leading technologies.